VYNE Therapeutics Inc, previously known as Menlo Therapeutics Inc., is a pharmaceutical company that is dedicated to the development and commercialization of unique and novel therapies specifically for dermatological conditions such as rosacea and acne. VYNE envisions a world where patients can have an uncompromised skin health and an improved quality of life. The successful creation of valuable medical treatments that help change lives is at the core of what defines this company.
The headquarters of VYNE Therapeutics Inc. is in Bridgewater, New Jersey. David Domzalski, an experienced pharmaceutical professional with expertise in strategic planning, sales, and marketing, is the Chief Executive Officer of the company. Over the years, VYNE has established itself as a significant player in the dermatology sector. Since its inception, it has been steadfast in its commitment to innovation and advancement in the field of dermatological medicine.
VYNE Therapeutics is best known for its innovative topical treatments, AMZEEQ and ZILXI. AMZEEQ™ (minocycline) topical foam, is the first topical form of minocycline approved by the US FDA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients. This product represents a significant milestone in acne therapy with it being the first new chemical entity approved for acne in decades. Following the success of AMZEEQ™, the company launched ZILXI™ (minocycline) topical foam, the first minocycline product of any kind to be approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.
Apart from these existing products, VYNE Therapeutics is committed to continuously striving to expand its portfolio of products and bring into the market more solutions for the unmet medical needs in dermatology. More importantly, it is dedicated to developing drugs that are not only innovative but also affordable.
As a company, VYNE Therapeutics also acknowledges its moral and ethical responsibilities as a corporate entity. This is evident in their commitment to environmental, social, and corporate governance. They are not only committed to delivering innovative solutions that improve patient outcomes but also believe in approaching the business operations responsibly, ethically, and with integrity.
In summary, VYNE Therapeutics is more than just a pharmaceutical company. It is a pioneer in the field of dermatology, creating innovative solutions to address unmet medical needs, while maintaining a commitment to positive corporate conduct. Their innovative products and their advances in medical research are a testament to their unwavering dedication to their mission and vision. VYNE Therapeutics thrives on its spirit of innovation, commitment to patient health, and dedication to corporate responsibility.